Parkinson&apos
Conditions
Interventions
This is a single-blind, parallel-group, randomized controlled trial with three arms. Sixty participants with Parkinson’s disease, aged between 50 and 80 years, will be randomized using random numbers
however, blinding of the therapist is not possible due to the nature of the intervention, in accordance with CONSORT guidelines
Sponsors
Universidade de São Paulo
Universidade de São Paulo
Eligibility
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria will include participants of both sexes, with functional walking deficits; but who are able to walk without an assistive device for at least 10 meters; weigh more than 30 kg; are able to respond to and understand commands; are in stages 1–3 of the Hoehn & Yahr scale; have medical supervision; and are available for the duration required by the study
Exclusion criteria
Exclusion criteria: Exclusion criteria will include patients with significant cognitive impairment; severe motor impairments such as disabling dyskinesias; extreme rigidity; or severe postural instability; as well as those who require the continuous use of walking aids. In addition, individuals with acute systemic or neurological comorbidities; severe joint deformities; uncontrolled epilepsy; sensitivity to visual stimulation, or uncorrected visual and vestibular impairments that hinder the safe execution of the protocol will not be included
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvements are expected in the spatiotemporal parameters of gait and in functional balance; gait speed in meters per second will be obtained using the 10-meter walk test and a motion capture system; cadence in steps per minute and step length in centimeters will also be analyzed to reflect gait rhythm and symmetry; functional balance will be assessed using the Berg Balance Scale, with a total score ranging from zero to fifty-six points | — |
Secondary
| Measure | Time frame |
|---|---|
| We expect to observe improvements in the gait symmetry index; we expect to observe changes in the kinetic and baropodometric parameters recorded in the motion analysis laboratory; we expect to monitor potential adverse events such as dizziness, fatigue, discomfort, motion sickness, or cyber-nausea during and after the intervention to assess the safety and tolerability of the protocol | — |
Countries
BR
Contacts
Public ContactGabriella Battaglion
Faculdade de Medicina de Ribeirão Preto
Outcome results
None listed